ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO429

Longitudinal Follow-Up and Outcomes for Patients with CKD in China: Results from the C-STRIDE Study

Session Information

Category: CKD (Non-Dialysis)

  • 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Wang, Jinwei, Renal Division, Department of Medicine, Peking University First Hospital; Peking University Institute of Nephrology, Beijing, BEIJING, China
  • Zhang, Luxia, Peking University Institute of Nephrology, Beijing, China
  • Zhao, Ming Hui, Peking University First Hospital, Beijing, China

Group or Team Name

  • C-STRIDE study group

We aimed to evaluate the longitudinal prognosis of chronic kidney disease (CKD) in China by comparing incidence rates of end-stage kidney disease (ESKD), cardiovascular disease (CVD) and death.


Totally, 3,700 participants of the C-STRIDE study, an ongoing cohort study with stage 1-4 CKD, were included. The outcomes were occurrence of ESKD, CVD, and death. Crude incidence rates were computed and expressed as the number of events per 100 patient-years. Cumulative incidence curves were depicted for the outcomes and stratified by age, eGFR and ACR, with the adjustment for other risk factors. Fine and Gray model was used in computing the cumulative incidence of ESKD and CVD.


The participants were 49.9±14.3 years, with 58.2% of male, 70.6% with eGFR<60ml/min/1.73m2 and 55.5% with ACR≥300mg/g. After a median follow-up of 5 years, the crude incidence rate of ESKD was about two times that of CVD (3.14/100 patient-years vs. 1.77/100 patient-years) and three times that of death (3.14/100 patient-years vs. 0.92/100 patient-years). The cumulative incidence of ESKD was significantly higher among those aged<55 years than the counterparts, while adverse situations were observed for CVD and death (all p-values<0.05). Higher cumulative incidence rate of ESKD was observed in those with eGFR<60ml/min/1.73m2 and ACR≥300mg/g, while much smaller gaps were detected for cumulative incidence rates of CVD and death (Figure).


Our study found a higher rate of ESKD than CVD or death in a prospective cohort study of patients with CKD in China. Advanced age was shown as protective factors for the risk of ESKD, while reduced eGFR and presence of albuminuria exacerbate the risk of ESKD, compared with their effect on the risk of CVD and death.

Multivariable adjusted cumulative incidence of ESKD, CVD and death stratified by age, eGFR and ACR categories


  • Government Support - Non-U.S.